Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/BCMA CAR-T cells in refractory scleroderma
NCT05085444Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in scleroderma, sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 90 days. Status: unknown.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
scleroderma
Beyond the preview
Go deeper on NCT05085444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085444.